论文部分内容阅读
１９９２年３月～１９９３年７月作者以个去甲氧基柔红霉素（ＩＤＡ）为主组成联合化疗方案治疗各种初治和复治的急性白血病共３６例，其中急性淋巴细胞白血病（ＡＬＬ）１５例，急性非淋巴细胞白血病（ＡＮＬＬ）２１例。ＡＬＬ组采用ＶＩＣＰ方案（其中ＩＤＡ１０～１５ｍｇ／ｄ，静脉注射，第１～３天和第１５～１７天）；ＡＮＬＬ组采用ＩＡ方案（其中ＩＤＡ１０～１５ｍｇ／ｄ，静脉注射，第１～３天）。结果表明ＩＤＡ安全、有效。初治ＡＬＬ的完全缓解（ＣＲ）率为７／１０（７０％），复治ＡＬＬ的ＣＲ率为１／５（２０％）；初治ＡＮＬＬ的ＣＲ率为６／１３例（４６％），复治ＡＮＬＬ的ＣＲ率为４／８例（５０％）。ＩＤＡ联合化疗的副作用与柔红霉素相仿，仍有一定的心脏毒性，在老年患者中应谨慎使用。
From March 1992 to July 1993, the authors treated a total of 36 newly treated and retreated acute leukemias with a combination of demethoxydromatomycin (IDA)-based chemotherapy regimen, including acute lymphoblastic leukemia ( Fifteen patients (ALL) and 21 patients with acute nonlymphocytic leukemia (ANLL). In the ALL group, the VICP regimen was used (IDA 10-15 mg/d, intravenous injection, 1st to 3rd days, and 15th to 17th days); the ANLL group was treated with an IA regimen (where IDA was 10-15 mg/d, intravenous injection, 1st to 3rd days) ). The results show that IDA is safe and effective. The complete remission (CR) rate of newly diagnosed ALL was 7/10 (70%), the CR rate of relapsed ALL was 1/5 (20%), and the CR rate of initial treatment of ANLL was 6/13 (46%). The CR rate for retreatment of ANLL was 4/8 (50%). The side effects of IDA combined with chemotherapy are similar to daunorubicin, which still has some cardiotoxicity and should be used with caution in elderly patients.